KR20200031134A - 항체 약물 접합체 커플링 이후의 미결합 약물의 제거 - Google Patents
항체 약물 접합체 커플링 이후의 미결합 약물의 제거 Download PDFInfo
- Publication number
- KR20200031134A KR20200031134A KR1020207004375A KR20207004375A KR20200031134A KR 20200031134 A KR20200031134 A KR 20200031134A KR 1020207004375 A KR1020207004375 A KR 1020207004375A KR 20207004375 A KR20207004375 A KR 20207004375A KR 20200031134 A KR20200031134 A KR 20200031134A
- Authority
- KR
- South Korea
- Prior art keywords
- ultrafiltration
- product stream
- capillary
- unit
- purification
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims description 31
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims description 31
- 239000003814 drug Substances 0.000 title description 26
- 229940079593 drug Drugs 0.000 title description 24
- 230000008878 coupling Effects 0.000 title description 2
- 238000010168 coupling process Methods 0.000 title description 2
- 238000005859 coupling reaction Methods 0.000 title description 2
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 128
- 238000000746 purification Methods 0.000 claims abstract description 72
- 239000012530 fluid Substances 0.000 claims abstract description 36
- 239000000126 substance Substances 0.000 claims abstract description 14
- 238000004140 cleaning Methods 0.000 claims abstract description 11
- 238000006073 displacement reaction Methods 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 44
- 231100000331 toxic Toxicity 0.000 claims description 36
- 230000002588 toxic effect Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- 239000012528 membrane Substances 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 10
- 229920002521 macromolecule Polymers 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 abstract description 15
- 239000000047 product Substances 0.000 description 125
- 238000011026 diafiltration Methods 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000012538 diafiltration buffer Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000012465 retentate Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000010977 unit operation Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000010924 continuous production Methods 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000002572 peristaltic effect Effects 0.000 description 5
- 238000010923 batch production Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012504 chromatography matrix Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920002145 PharMed Polymers 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000237983 Trochidae Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 objects Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/243—Dialysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/246—Membrane extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/28—Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/08—Specific process operations in the concentrate stream
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Water Supply & Treatment (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17182039.2 | 2017-07-19 | ||
| EP17182039.2A EP3431168A1 (en) | 2017-07-19 | 2017-07-19 | Élimination de médicament non lié après couplage conjugué anticorps-médicament |
| PCT/EP2018/068970 WO2019016070A1 (en) | 2017-07-19 | 2018-07-12 | DISPOSAL OF NON-BOUND MEDICINAL PRODUCT AFTER CONJUGATED COUPLING MEDICINE-ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200031134A true KR20200031134A (ko) | 2020-03-23 |
Family
ID=59520721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207004375A KR20200031134A (ko) | 2017-07-19 | 2018-07-12 | 항체 약물 접합체 커플링 이후의 미결합 약물의 제거 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200206688A1 (ja) |
| EP (2) | EP3431168A1 (ja) |
| JP (1) | JP2020527102A (ja) |
| KR (1) | KR20200031134A (ja) |
| CN (1) | CN111093810A (ja) |
| AR (1) | AR112612A1 (ja) |
| AU (1) | AU2018304504A1 (ja) |
| BR (1) | BR112020001058A2 (ja) |
| CA (1) | CA3070113A1 (ja) |
| IL (1) | IL271949A (ja) |
| RU (1) | RU2020107296A (ja) |
| SG (1) | SG11202000264TA (ja) |
| TW (1) | TW201919747A (ja) |
| WO (1) | WO2019016070A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201934187A (zh) * | 2018-01-12 | 2019-09-01 | 美商免疫遺傳股份有限公司 | 抗體藥物結合、純化、及調配之方法 |
| EP3939691B1 (en) * | 2020-07-13 | 2023-11-22 | Sartorius Stedim Biotech GmbH | Device assembly for producing bioconjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4670077B2 (ja) * | 2004-10-04 | 2011-04-13 | 独立行政法人産業技術総合研究所 | 生理活性高分子物質の精製方法及びその方法により得られる精製物 |
| CN102716480B (zh) * | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| CN101219846B (zh) * | 2008-01-23 | 2010-12-01 | 哈尔滨工业大学 | 超滤膜混凝/吸附/生物反应器一体化水深度处理方法及其装置 |
| CN103619357A (zh) * | 2011-03-29 | 2014-03-05 | 伊缪诺金公司 | 用于制造具有改善的同质性的缀合物的方法 |
| US9650411B2 (en) * | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
| TWI596107B (zh) * | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
| EP2907565A1 (de) * | 2014-02-17 | 2015-08-19 | Bayer Technology Services GmbH | Dialyse-Einheit zum kontinuierlichen Puffer- bzw. Medienaustausch aus einer Proteinlösung |
| EP3236772A4 (en) * | 2014-12-22 | 2018-10-17 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| EP3015542A1 (de) * | 2015-05-07 | 2016-05-04 | Bayer Technology Services GmbH | Modulare anlage und verfahren zur kontinuierlichen, keimreduzierten produktion und/oder aufbereitung eines produktes |
-
2017
- 2017-07-19 EP EP17182039.2A patent/EP3431168A1/en not_active Withdrawn
-
2018
- 2018-07-12 AU AU2018304504A patent/AU2018304504A1/en not_active Abandoned
- 2018-07-12 EP EP18743719.9A patent/EP3655137A1/en not_active Withdrawn
- 2018-07-12 KR KR1020207004375A patent/KR20200031134A/ko not_active Application Discontinuation
- 2018-07-12 SG SG11202000264TA patent/SG11202000264TA/en unknown
- 2018-07-12 WO PCT/EP2018/068970 patent/WO2019016070A1/en unknown
- 2018-07-12 CN CN201880059650.XA patent/CN111093810A/zh active Pending
- 2018-07-12 JP JP2020502328A patent/JP2020527102A/ja active Pending
- 2018-07-12 CA CA3070113A patent/CA3070113A1/en not_active Abandoned
- 2018-07-12 BR BR112020001058-8A patent/BR112020001058A2/pt not_active Application Discontinuation
- 2018-07-12 RU RU2020107296A patent/RU2020107296A/ru unknown
- 2018-07-12 US US16/631,326 patent/US20200206688A1/en not_active Abandoned
- 2018-07-17 TW TW107124586A patent/TW201919747A/zh unknown
- 2018-07-19 AR ARP180102022 patent/AR112612A1/es unknown
-
2020
- 2020-01-09 IL IL271949A patent/IL271949A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201919747A (zh) | 2019-06-01 |
| SG11202000264TA (en) | 2020-02-27 |
| EP3655137A1 (en) | 2020-05-27 |
| AR112612A1 (es) | 2019-11-20 |
| US20200206688A1 (en) | 2020-07-02 |
| AU2018304504A1 (en) | 2020-01-30 |
| CA3070113A1 (en) | 2019-01-24 |
| BR112020001058A2 (pt) | 2020-07-14 |
| WO2019016070A1 (en) | 2019-01-24 |
| IL271949A (en) | 2020-02-27 |
| CN111093810A (zh) | 2020-05-01 |
| EP3431168A1 (en) | 2019-01-23 |
| RU2020107296A (ru) | 2021-08-19 |
| JP2020527102A (ja) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201706403A (zh) | 用於連續減少微生物產生及／或處理產物的模組化系統與方法 | |
| ES2894696T3 (es) | Método para la reducción o eliminación de uno o más componentes de un producto sanguíneo | |
| KR20200032134A (ko) | 가이던스 분자 약물 접합체의 연속적 제조 | |
| EP2771087A1 (en) | A method for extracorporeal elimination of one or more components from blood | |
| GB2572275A (en) | Method for preparing Foot-and-Mouth disease vaccine | |
| KR20200031134A (ko) | 항체 약물 접합체 커플링 이후의 미결합 약물의 제거 | |
| WO1997018844A1 (en) | Inactivation method and system in biological fluids | |
| WO2011046504A1 (en) | Method and product for blood treatment and purification | |
| TW202041531A (zh) | 用於將批式生產程序轉移至連續生產程序之方法 | |
| TW201831889A (zh) | 取樣流體流以監控連續流中汙染物之方法 | |
| JP2011036128A (ja) | 抗体製造方法 | |
| JP2018082987A (ja) | ウイルス不活化方法及びウイルス不活化装置 | |
| US20230355849A1 (en) | Kit and method for reduction of components in a blood-related medium | |
| WO2024127218A1 (en) | Process of manufacturing a device and device for the treatment of fluids | |
| WO1997012915A1 (es) | Procedimiento de purificacion del factor de transferencia a partir de leucocitos | |
| JP2006522024A (ja) | 無菌様式での自然源からのタンパク質の単離 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |